查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016121

腦膜炎雙球菌疫苗市場報告：按疫苗類型、成分、疫苗血清型、分銷管道、最終用戶和地區分類（2026-2034 年）

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年全球腦膜炎雙球菌疫苗市場規模達42億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到78億美元，2026年至2034年的複合年成長率為7.01%。腦膜炎雙球菌病菌感染負擔日益加重、政府免疫接種計劃、持續的技術進步以及對全球衛生安全的擔憂是推動市場成長的主要因素。

腦膜炎雙球菌疫苗市場趨勢：

病菌感染發生率上升

腦膜炎球菌病菌感染率的上升是腦膜炎球菌疫苗需求成長的關鍵促進因素。例如，根據世界衛生組織（世衛組織）統計，2022年11月至2023年1月期間，尼日爾東南部津德爾地區記錄了約559例腦膜炎病例，其中18例死亡。這一數字較2021年11月至2022年1月期間報告的231例有所增加。腦膜炎雙球菌病菌感染由腦膜炎奈瑟菌引起，由於其發病迅速、病情嚴重且易集體爆發，仍是全球重要的公共衛生議題。如此高的疾病負擔推動了對有效疫苗的需求。這些因素表明，腦膜炎雙球菌疫苗市場將在未來幾年內持續成長。

擴大宣傳活動

公共衛生宣傳活動、醫護人員教育以及社區宣傳活動正在提高公眾對腦膜炎球菌病菌感染和疫苗接種重要性的認知。例如，葛蘭素史克公司於2021年8月發起了「Ask2BSure」公共衛生宣傳活動，鼓勵家長諮詢孩子的醫生，了解孩子是否接種過B群腦膜炎雙球菌疫苗。病菌感染疾病，俗稱腦膜炎，是一種罕見但可能危及生命的疾病。提高公眾對該疾病的認知將有助於提高疫苗的接受度和接種率。這些因素也對腦膜炎雙球菌疫苗市場前景產生了正面影響。

政府疫苗接種計劃

許多國家已製定常規免疫接種計劃，包括為嬰幼兒、青少年和高風險族群接種腦膜炎雙球菌疫苗。例如，根據西澳大利亞衛生署2022年11月發布的最新信息，學校免疫計劃（SBIP）將於2023年開始為學生提供白喉、破傷風和百日咳（dTpa）、人類乳突病毒（HPV）和腦膜炎球菌ACWY疫苗。同樣，昆士蘭州政府於2023年8月宣布，計劃在未來三年內投資9,000萬美元，為嬰幼兒和成人免費提供B群腦膜炎雙球菌疫苗，預計將提振腦膜炎雙球菌疫苗市場的收入。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球腦膜炎雙球菌疫苗市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疫苗類型分類

  • 組合型
  • 多醣
  • 囊下

第7章 市場構成細分：依構成

  • 單價疫苗
  • 聯合疫苗

第8章 市場區隔：依疫苗血清型分類

  • MenACWY
  • MenB 和 Manic
  • MenC
  • MenA
  • MenAC
  • 其他

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 向公共機構銷售
  • 其他

第10章 市場區隔：依最終用戶分類

  • 兒童
  • 成人

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • GlaxoSmithKline Plc
    • Hualan Biological Engineering Inc.
    • Incepta Pharmaceuticals Limited
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Serum Institute of India Ltd.
    • Walvax Biotechnology Co. Ltd.
Product Code: SR112026A2730

The global meningococcal vaccines market size reached USD 4.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 7.8 Billion by 2034, exhibiting a growth rate (CAGR) of 7.01% during 2026-2034. The increasing burden of meningococcal disease, government immunization programs, ongoing technological advancements, and global health security concerns are driving the primarily driving the market growth.

Meningococcal Vaccines Market Trends:

Rising Prevalence of Meningococcal Disease

The rising prevalence of meningococcal disease is a significant factor driving the demand for meningococcal vaccines. For instance, according to the World Health Organization (WHO), from November 2022 to January 2023, around 559 cases of meningitis, including 18 deaths, were recorded from Zinder Region, southeast of Niger, compared to 231 cases reported from November 2021 to January 2022. Meningococcal disease, caused by Neisseria meningitidis bacteria, remains a significant global health concern due to its potential for rapid onset, severity, and outbreaks. The high disease burden drives the demand for effective vaccines. These factors are expected to propel the meningococcal vaccines market in the coming years.

Increasing Awareness Programs

Public health campaigns, healthcare provider education, and community outreach efforts have increased awareness about meningococcal disease and the importance of vaccination. For instance, in August 2021, GSK introduced "Ask2BSure," a public health campaign to encourage parents to check with their child's doctor to see if they have meningitis B immunization. Meningococcal disease, often known as meningitis, is a rare but potentially fatal condition. Enhanced understanding promotes vaccine acceptance and uptake. These factors further positively influence the meningococcal vaccines market forecast.

Government Immunization Programs

Many countries have established routine immunization schedules that include meningococcal vaccines, targeting infants, adolescents, and high-risk groups. For example, according to a November 2022 update from the Government of Western Australia Department of Health, the School-Based Immunization Program (SBIP) would provide Diphtheria-tetanus-pertussis (dTpa), HPV (human papillomavirus), and Meningococcal ACWY vaccines to students beginning 2023. Similarly, in August 2023, the Queensland Government planned to invest US$ 90 million over the next three years to offer free meningococcal B vaccine vaccinations for young children and adults, thereby boosting the meningococcal vaccine systems market revenue.

Global Meningococcal Vaccines Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global meningococcal vaccines market report, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on vaccine type, composition, vaccine serotype, distribution channel, and end user.

Breakup by Vaccine Type:

  • Conjugate
  • Polysaccharide
  • Subcapsular

According to the meningococcal vaccines market outlook, conjugate vaccines are composed of polysaccharide antigens from the bacterial capsule of Neisseria meningitidis, chemically linked (conjugated) to a carrier protein. While polysaccharide vaccines contain purified polysaccharide antigens derived from the bacterial capsule of Neisseria meningitidis. Moreover, subcapsular vaccines target specific surface proteins or antigens located within the bacterial capsule or outer membrane of Neisseria meningitidis.

Breakup by Composition:

  • Mono Vaccines
  • Combination Vaccines

According to the meningococcal vaccines market overview, monovalent vaccines are often in demand during outbreaks or localized epidemics caused by specific meningococcal serogroup. Public health authorities may deploy monovalent vaccines to quickly contain outbreaks and prevent further spread of the disease. While combination vaccines that protect against multiple meningococcal serogroups (e.g., MenACWY) are favored for routine immunization schedules. They streamline vaccination programs by reducing the number of injections and clinic visits required to achieve comprehensive protection.

Breakup by Vaccine Serotype:

  • MenACWY
  • MenB & Manic
  • MenC
  • MenA
  • MenAC
  • Others

MenACWY vaccines protect against meningococcal serogroups A, C, W, and Y. While MenB vaccines target meningococcal serogroup B. MenB vaccines are typically recombinant protein-based or outer membrane vesicle (OMV) vaccines. They contain antigens specific to serogroup B, which are distinct in structure from serogroups A, C, W, and Y. Moreover, MenAC vaccines target meningococcal serogroups A and C. Apart from this, MenA vaccines specifically target meningococcal serogroup A. These are typically monovalent vaccines containing polysaccharide antigens from serogroup A Neisseria meningitidis. Furthermore, MenACWY-DT vaccines combine antigens from meningococcal serogroups A, C, W, and Y.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Hospitals often administer meningococcal vaccines to patients admitted for various reasons, including those at higher risk of contracting meningococcal disease due to immunocompromised status or underlying conditions. Hospital pharmacies may provide vaccinations to individuals requiring preventive care or as part of travel medicine services. While retail pharmacies cater to the general public, offering convenient access to meningococcal vaccines for individuals seeking preventive healthcare. Apart from this, institutional sales involve large-scale procurement of meningococcal vaccines for public health programs, such as national immunization schedules targeting specific age groups or high-risk populations.

Breakup by End User:

  • Pediatric
  • Adult

Meningococcal vaccines, such as MenACWY, are included in routine childhood immunization schedules in many countries. Vaccination typically begins in infancy and continues through childhood, with doses administered according to national guidelines. While young adults who missed meningococcal vaccination during adolescence may receive catch-up doses, especially before entering college or university. College and university dormitories often require proof of meningococcal vaccination, boosting demand among this age group.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the meningococcal vaccines market statistics, the rising prevalence of meningococcal disease in North America is a primary driver. Meningococcal infections can lead to severe outcomes, including meningitis and sepsis, which have spurred vaccination efforts. While stringent healthcare policies and regulations in Europe support the adoption and inclusion of meningococcal vaccines in national immunization schedules. This regulatory environment provides stability and encourages vaccine development and distribution. Apart from this, the Asia Pacific region has seen an increase in the incidence of meningococcal disease, prompting higher demand for vaccines.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Incepta Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Ltd.
  • Walvax Biotechnology Co. Ltd.

Key Questions Answered in This Report

  • How has the global meningococcal vaccines market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global meningococcal vaccines market?
  • What are the key regional markets?
  • What is the breakup of the market based on the vaccine type?
  • What is the breakup of the market based on the composition?
  • What is the breakup of the market based on the vaccine serotype?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global meningococcal vaccines market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Meningococcal Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Conjugate
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polysaccharide
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subcapsular
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Composition

  • 7.1 Mono Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Combination Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Vaccine Serotype

  • 8.1 MenACWY
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 MenB & Manic
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 MenC
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 MenA
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 MenAC
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Institutional Sales
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Pediatric
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Adult
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 GlaxoSmithKline Plc
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Hualan Biological Engineering Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Incepta Pharmaceuticals Limited
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Novartis AG
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Pfizer Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Sanofi S.A.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Serum Institute of India Ltd.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Walvax Biotechnology Co. Ltd.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials

List of Figures

  • Figure 1: Global: Meningococcal Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Meningococcal Vaccines Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Meningococcal Vaccines Market: Breakup by Vaccine Type (in %), 2025
  • Figure 4: Global: Meningococcal Vaccines Market: Breakup by Composition (in %), 2025
  • Figure 5: Global: Meningococcal Vaccines Market: Breakup by Vaccine Serotype (in %), 2025
  • Figure 6: Global: Meningococcal Vaccines Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Meningococcal Vaccines Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Meningococcal Vaccines Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Meningococcal Vaccines Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 10: Global: Meningococcal Vaccines (Conjugate) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Meningococcal Vaccines (Conjugate) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Meningococcal Vaccines (Polysaccharide) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Meningococcal Vaccines (Polysaccharide) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Meningococcal Vaccines (Subcapsular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Meningococcal Vaccines (Subcapsular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Meningococcal Vaccines (Mono Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Meningococcal Vaccines (Mono Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Meningococcal Vaccines (Combination Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Meningococcal Vaccines (Combination Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Meningococcal Vaccines (MenACWY) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Meningococcal Vaccines (MenACWY) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Meningococcal Vaccines (MenB & Manic) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Meningococcal Vaccines (MenB & Manic) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Meningococcal Vaccines (MenC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Meningococcal Vaccines (MenC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Meningococcal Vaccines (MenA) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Meningococcal Vaccines (MenA) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Meningococcal Vaccines (MenAC) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Meningococcal Vaccines (MenAC) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Meningococcal Vaccines (Other Vaccine Serotypes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Meningococcal Vaccines (Other Vaccine Serotypes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Meningococcal Vaccines (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Meningococcal Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Meningococcal Vaccines (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Meningococcal Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Meningococcal Vaccines (Institutional Sales) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Meningococcal Vaccines (Institutional Sales) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Meningococcal Vaccines (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Meningococcal Vaccines (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Meningococcal Vaccines (Pediatric) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Meningococcal Vaccines (Pediatric) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Meningococcal Vaccines (Adult) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Meningococcal Vaccines (Adult) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: North America: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: North America: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: United States: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: United States: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Canada: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Canada: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Asia Pacific: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Asia Pacific: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: China: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: China: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Japan: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Japan: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: India: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: India: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: South Korea: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: South Korea: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Australia: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Australia: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Indonesia: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Indonesia: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Europe: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Europe: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Germany: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Germany: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: France: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: France: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: United Kingdom: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: United Kingdom: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Italy: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Italy: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Spain: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Spain: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Russia: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Russia: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Latin America: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Latin America: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Brazil: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Brazil: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Mexico: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Mexico: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Others: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Others: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Middle East and Africa: Meningococcal Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Middle East and Africa: Meningococcal Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Global: Meningococcal Vaccines Industry: SWOT Analysis
  • Figure 93: Global: Meningococcal Vaccines Industry: Value Chain Analysis
  • Figure 94: Global: Meningococcal Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Meningococcal Vaccines Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Meningococcal Vaccines Market Forecast: Breakup by Vaccine Type (in Million USD), 2026-2034
  • Table 3: Global: Meningococcal Vaccines Market Forecast: Breakup by Composition (in Million USD), 2026-2034
  • Table 4: Global: Meningococcal Vaccines Market Forecast: Breakup by Vaccine Serotype (in Million USD), 2026-2034
  • Table 5: Global: Meningococcal Vaccines Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Meningococcal Vaccines Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 7: Global: Meningococcal Vaccines Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Meningococcal Vaccines Market: Competitive Structure
  • Table 9: Global: Meningococcal Vaccines Market: Key Players